Answers are grounded in this paper and cite their sources.
Dry powder inhalers (DPIs) are widely used in the clinical practice for delivering therapeutics to patients with lung diseases, such as chronic obstructive pulmonary disease. An overview of current DPIs available on the market from high resistance to low resistance has been reported in a recent review article. We assessed this concept review article and believe this letter provides important additional information regarding the correct interpretation of the data on low resistance DPIs.
No takes yet. Share an insight, caveat, or question.
Price et al. (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: